Marketing Rights Acquisitions, PDUFA Date Extensions, Accountable Care Relationship and Stock Price Updates - Research Report on Forest Laboratories, Biogen, Bristol-Myers, Express Scripts, and Aetna PR Newswire NEW YORK, December 5, 2013 NEW YORK, December 5, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Forest Laboratories, Inc. (NYSE: FRX), Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), Express Scripts Holding Company (NASDAQ: ESRX), and Aetna Inc. (NYSE: AET). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Forest Laboratories, Inc. Research Report On December 2, 2013, Forest Laboratories, Inc. (Forest Laboratories) reported that its wholly owned subsidiary, Forest Laboratories Holding Limited (FLHL) is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V. (Merck Sharp), a wholly owned subsidiary of Merck & Co., Inc. Forest Laboratories informed that under the terms of the agreement FLHL will make an upfront payment of $240 million and additional payments to Merck Sharp based on defined sales milestones. The Company also reported that Merck Sharp will remain responsible for product supply, and FLHL will take over the responsibility for continued commercialization, including completing certain post marketing studies of Saphris, following a transition period, and will be the marketing authorization holder. The Company expects the agreement to close in early 2014 pending regulatory review and satisfaction of all closing conditions. The Full Research Report on Forest Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/ea24_FRX Biogen Idec Inc. Research Report On December 2, 2013, Biogen Idec Inc. (Biogen Idec) announced that the US Food and Drug Administration (FDA) has extended the initial Prescription Drug User Free Act (PDUFA) date for its review of the Biologics License Application (BLA) for ALPROLIX, the Company's investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B. Biogen Idec informed that the PDUFA date was extended by three months, which is the standard extension period. Biogen Idec added that in response to a request from the FDA, it has submitted additional information related to the validation of a manufacturing step for ALPROLIX. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/b95b_BIIB Bristol-Myers Squibb Co. Research Report On December 2, 2013, Bristol-Myers Squibb Co.'s (Bristol-Myers) stock rose 0.19%, ending the day's session at $51.48. Over the previous three trading sessions, shares of Bristol-Myers declined 0.77%, compared to the S&P 500 Index, which declined 0.10% during the same period. The Full Research Report on Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/81a9_BMY Express Scripts Holding Company Research Report On December 2, 2013, Express Scripts Holding Company (Express Scripts) declined 0.48%, ending the day's session at $67.03. Over the previous three trading sessions, shares of Express Scripts declined 0.34%, compared to the Nasdaq Composite Index, which gained 0.68% during the same period. The Full Research Report on Express Scripts Holding Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/91a7_ESRX Aetna Inc. Research Report On December 2, 2013, Aetna Inc. (Aetna) and PinnacleHealth System jointly announced a new accountable care agreement, designed to improve the quality of care and lower overall health care costs for Aetna commercial plan members in the Harrisburg, Pennsylvania, area. According to Aetna, the collaboration will use PinnacleHealth's comprehensive, integrated system of physicians, hospitals, and ambulatory services to give area employers better health care options for their employees by - creating a more coordinated patient experience, saving employees money when they use providers aligned with PinnacleHealth, and improving health care outcomes. Aetna added that it will introduce both fully insured and self-insured health plans in Central Pennsylvania that will use PinnacleHealth's community-based systems of care and its network of highly respected physicians. Aetna expects the first product, for groups of more than 51 employees, to be available on April 1, 2014, and a small-group product for groups of between two and 50 employees to be introduced on July 1, 2014. The Full Research Report on Aetna Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/cbe9_AET EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Marketing Rights Acquisitions, PDUFA Date Extensions, Accountable Care Relationship and Stock Price Updates - Research Report on
Press spacebar to pause and continue. Press esc to stop.